These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15808955)

  • 1. Molecular markers of prostate cancer outcome.
    Quinn DI; Henshall SM; Sutherland RL
    Eur J Cancer; 2005 Apr; 41(6):858-87. PubMed ID: 15808955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomolecular markers of outcome prediction in prostate cancer.
    Lopergolo A; Zaffaroni N
    Cancer; 2009 Jul; 115(13 Suppl):3058-67. PubMed ID: 19544547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers in prostate cancer.
    Ross JS; Sheehan CE; Fisher HA; Kauffman RA; Dolen EM; Kallakury BV
    Expert Rev Mol Diagn; 2002 Mar; 2(2):129-42. PubMed ID: 11962333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
    Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
    Knudsen BS; Miranti CK
    J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
    Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
    J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
    Voorzanger-Rousselot N; Garnero P
    Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
    Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
    Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review).
    Wu J
    Anticancer Res; 1996; 16(4B):2233-9. PubMed ID: 8694549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers in bladder cancer.
    Shariat SF; Karam JA; Lerner SP
    Curr Opin Urol; 2008 Jan; 18(1):1-8. PubMed ID: 18090481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor decoy molecules block the growth of prostate cancer.
    Quayle SN; Mawji NR; Wang J; Sadar MD
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1331-6. PubMed ID: 17227854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-apoptotic effect of the androgen receptor in human prostate cancer].
    Shen FY; Li BY
    Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1121-4. PubMed ID: 18284065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.